Multiple myeloma maintenance therapy following autologous hematopoietic stem cell transplantation

Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of abnormal plasma cells in the bone marrow, often leading to bone lesions, hypercalcemia, anemia, renal impairment, and immunosuppression

In the post-remission setting for eligible patients who have completed induction chemotherapy and conditioning followed by autologous hematopoietic stem cell transplantation, the clinical state is defined by achieved remission or stable disease accompanied by persistent minimal residual disease Maintenance therapy in this specific context represents prolonged, low-toxicity antineoplastic treatment administered to suppress remaining clonal plasma cells, delay disease progression, and sustain or d...

In the post-remission setting for eligible patients who have completed induction chemotherapy and conditioning followed by autologous hematopoietic stem cell transplantation, the clinical state is defined by achieved remission or stable disease accompanied by persistent minimal residual disease Maintenance therapy in this specific context represents prolonged, low-toxicity antineoplastic treatment administered to suppress remaining clonal plasma cells, delay disease progression, and sustain or d...

Maintenance therapy in this specific context represents prolonged, low-toxicity antineoplastic treatment administered to suppress remaining clonal plasma cells, delay disease progression, and sustain or deepen treatment response